Novartis and Xencor enter into bispecific antibody agreement

June 28, 2016 5:34 AM

21 0

Novartis and Xencor enter into bispecific antibody agreement

ZURICH Novartis has received rights with Xencor to develop bispecific antibodies for treating cancer.

"Under the terms of the agreement, Xencor is receiving a $150 million upfront payment from Novartis and the two companies will equally share the cost to jointly develop two Xencor antibodies targeting the CD3 domain," Novartis said.

Also read: Eurowings settles pay dispute with airline cabin crew

Read more

To category page

Loading...